AMNEAL PHARMACEUTICALS, INC. (AMRX) Net margin 2016–2025
AMNEAL PHARMACEUTICALS, INC. (AMRX) net profit margin by fiscal year — reported net income divided by reported revenue.
2.4%FY2025 · since FY2016: 0.0% → 2.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 2.4% | +6.6 pp |
| FY2024 | -4.2% | -0.7 pp |
| FY2023 | -3.5% | +8.7 pp |
| FY2022 | -12.2% | -12.9 pp |
| FY2021 | 0.6% | -2.8 pp |
| FY2020 | 3.4% | +40.5 pp |
| FY2019 | -37.1% | -35.9 pp |
| FY2018 | -1.2% | -1.2 pp |
| FY2017 | 0.0% | +0.0 pp |
| FY2016 | 0.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More AMRX financial trends
AMRX RevenueAMRX Net incomeAMRX Gross profitAMRX Gross marginAMRX Operating incomeAMRX Operating marginAMRX Operating cash flowAMRX Free cash flowAMRX Capital expendituresAMRX Return on equityAMRX Stock buybacksAMRX Dividends paidAMRX Total assetsAMRX Total liabilitiesAMRX Shareholders’ equityAMRX overview →